Patients wait more than six times longer for new medicines in neighboring European countries. The survey titled “EFPIA Patients Wait”, carried out by the European Federation of Pharmaceutical Industries and Associations (EFPIA), and the EFPIA/CRA (Charles River Associates) analysis, are intended to serve as starting points for a discussion on the main causes of unavailability of and delays in treatment across Europe, which are multifactorial and can be resolved only through the cooperation of all stakeholders in the system.
The annual survey titled “EFPIA Patients WAIT”, conducted by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and designed with the support of IQVIA, showed that patients in neighboring countries wait at least six times longer for access to new medicines. Speaking about the published survey and report, EFPIA Director General Nathalie Moll said: “The EU Pharmaceutical Strategy Plan also includes the goal of ensuring that patients in Europe have access to the medicines they need.” This is a shared goal and responsibility that the research-based pharmaceutical industry in Europe shares with patients, clinicians, healthcare systems, and governments across the EU. In order to better understand the real availability of medicines for patients in Europe and to support collaborative solutions that put patients’ needs first, EFPIA carried out its annual “Patients W.A.I.T. Indicator Survey” (IQVIA, 2020) and complemented it with an analysis of the results in a report entitled “The root cause of unavailability and delay to innovative medicines: shortening the time to patient access to innovative medicines.”
